The phase 1/2 DREAMM-4 study evaluated the combination of a B-cell maturation antigen–directed antibody-drug conjugate, belantamab mafodotin (belamaf), plus pembrolizumab in patients with heavily pretreated, triple class–exposed relapsed/refractory multiple myeloma. Of the 34 patients (n = 6 part 1, n = 28 part 2) who received 2.5 mg/kg belamaf plus pembrolizumab included in this final analysis, 16 (47%) had an overall response, with 29% having a very good partial response or better. The median progression-free survival was 3.4 months (95% CI, 1.4–5.6). The addition of pembrolizumab ..read more

Abstract Introduction Older adults with cancer facing competing treatments must prioritize between various outcomes. This study assessed health outcome prioritization among older adults with cancer starting chemotherapy. Methods Secondary analysis of a randomized trial addressing vulnerabilities in older adults with cancer. Patients completed three validated outcome prioritization tools: 1) Health Outcomes Tool: prioritizes outcomes (survival, independence, symptoms) using a visual analog scale; 2) Now vs. Later Tool: rates the importance of quality of life at three times—today versus 1 or 5 y ..read more

Cancer, EarlyView ..read more

Abstract Tagraxofusp is a first-in-class CD123-directed conjugate of an amended diphtheria toxin platform and recombinant interleukin 3. Binding and subsequent internalization of the drug result in cell death via disruption of intracellular protein synthesis. CD123 is a surface marker that is expressed in several hematological malignancies, especially blastic plasmacytoid dendritic cell neoplasm (BPDCN), where its expression is ubiquitous. A pivotal study of tagraxofusp in BPDCN resulted in its approval for the treatment of BPDCN, the first treatment approved for this indication. Since the int ..read more

Abstract Endometrial cancer continues to be the only gynecologic malignancy with a rising incidence and mortality, with both regional and global implications. Combination carboplatin and paclitaxel has been the recognized chemotherapy backbone for the treatment of advanced-stage or recurrent disease, with modest clinical outcomes. Over the last year, significant advances were achieved in improving oncologic outcomes by capitalizing on the molecular characterization of this heterogenous disease. These advances include incorporation of immunotherapy, identification of effective hormonal approach ..read more

Abstract Background Bereaved parents experience life-long grief after the death of their child from cancer. Parents who can integrate their grief and maintain their social functioning early in bereavement, even in the setting of concurrent psychosocial distress, have improved outcomes. Identifying the factors associated with bereaved parents' early social functioning can guide future supportive interventions. Methods The authors surveyed parents of children who died from cancer at two large centers 6–24 months after death, assessing bereavement experiences using validated and pilot tested tool ..read more

Cancer, Volume 130, Issue 9, Page 1546-1547, 1 May 2024 ..read more

Cancer, Volume 130, Issue 9, Page 1547-1548, 1 May 2024 ..read more

Cancer, Volume 130, Issue 9, Page 1548-1548, 1 May 2024 ..read more

No abstract is available for this article ..read more